MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.currproblcancer.2026.101301

Медицинская библиотека · Current problems in cancer · 2026

BCMA-directed CAR-T cell therapy in relapsed/refractory multiple myeloma: efficacy, safety, survival, and future directions - A systematic review and meta-analysis.

Mannan Muhammad Shaheer, Musheer Adeena, Khan Muhammad Waqas, Abbas Hur, Jillani Sheikh Abdul Qadir, Hafeez Ali Shan

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

BACKGROUND

Multiple myeloma is an incurable hematologic malignancy, although therapeutic advances have improved survival. BCMA-directed CAR-T cell therapy has shown high response rates in relapsed or refractory multiple myeloma (RRMM), but efficacy and toxicity vary across trials. A rigorous synthesis of current evidence is needed to better define these outcomes.

METHODS

We performed a systematic review and meta-analysis of prospective interventional trials published from inception to January 2026 evaluating BCMA-targeted CAR-T therapies in adults with RRMM. Trials reporting efficacy or safety outcomes were included. Pooled estimates with 95% confidence intervals (CI) were calculated in R. Heterogeneity was assessed using the I² statistic, publication bias with Egger's regression, and stability with leave-one-out sensitivity analysis.

RESULTS

Fourteen clinical trials including 1,278 patients with RRMM and a median of 3 to 8 prior lines of therapy were included1-4. The pooled overall response rate (ORR) was 86% (95% CI: 80-90%; I² = 75.9%). Grade ≥ 3 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 3% of patients (95% CI: 2-4%; I² = 0%). Discontinuation due to toxicity occurred in 4% (95% CI: 1-9%; I² = 68.2%), and treatment-related mortality in 5% (95% CI: 3-9%; I² = 64%). Additional efficacy and safety outcomes, including disease control rate and grade ≥ 3 hematologic toxicities, were also assessed.

CONCLUSION

BCMA-directed CAR-T cell therapy demonstrates high efficacy in RRMM with a low incidence of severe neurotoxicity. However, severe hematologic toxicities are frequent and treatment-related mortality remains clinically relevant, highlighting the need for optimized patient selection and toxicity mitigation.

Для цитирования: Mannan Muhammad Shaheer, Musheer Adeena, Khan Muhammad Waqas, Abbas Hur, Jillani Sheikh Abdul Qadir, Hafeez Ali Shan. BCMA-directed CAR-T cell therapy in relapsed/refractory multiple myeloma: efficacy, safety, survival, and future directions - A systematic review and meta-analysis.. Current problems in cancer. 2026. DOI: 10.1016/j.currproblcancer.2026.101301.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.